Hydrogen sulfide therapeutics and H2S-donating agents demonstrate multiple beneficial cardiovascular effects, including vasodilation, anti-inflammatory actions, and protection in cardiorenal syndrome.
Hydrogen sulfide is a critical regulator of cardiovascular homeostasis, and novel H2S-donating agents hold therapeutic potential for cardiovascular disease and cardiorenal syndrome.
Hydrogen sulfide (H 2 S)—a potent gaseous signaling molecule—has emerged as a critical regulator of cardiovascular homeostasis. H 2 S is produced enzymatically by 3 constitutively active endogenous enzymes in all mammalian species. Within the past 2 decades, studies administering H 2 S-donating agents and the genetic manipulation of H 2 S-producing enzymes have revealed multiple beneficial effects of H 2 S, including vasodilation, activation of antiapoptotic and antioxidant pathways, and anti-inflammatory effects. More recently, the heightened enthusiasm in this field has shifted to the development of novel H 2 S-donating agents that exert favorable pharmacological profiles. This has led to the discovery of novel H 2 S-mediated signaling pathways. This review will discuss recently developed H 2 S therapeutics, introduce signaling pathways that are influenced by H 2 S-dependent sulfhydration, and explore the dual-protective effect of H 2 S in cardiorenal syndrome.
Li et al. (Fri,) conducted a review in Cardiovascular Disease and Cardiorenal Syndrome. Hydrogen sulfide (H2S) therapeutics was evaluated. Hydrogen sulfide therapeutics and H2S-donating agents demonstrate multiple beneficial cardiovascular effects, including vasodilation, anti-inflammatory actions, and protection in cardiorenal syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: